Retevmo

Retevmo Benefits: High Response Rates, Durable Remissions, and CNS Activity

Retevmo delivers clinical outcomes that set it apart from anything that came before it in RET-altered cancers. In the pivotal LIBRETTO-001 trial, treatment-naive patients with RET fusion-positive non-small cell lung cancer achieved objective response rates exceeding 84%, with a median duration of response of more than 20 months. For a population that previously lacked a truly targeted option, these results represent a fundamental shift in what treatment can offer.

In RET-mutant medullary thyroid cancer — where RET mutations are the primary driver in virtually all hereditary cases and the majority of sporadic cases — response rates of approximately 69–73% were achieved across both previously treated and treatment-naive cohorts. Responses were consistent and durable, with many patients maintaining disease control well beyond a year of treatment.

One of Retevmo’s most clinically significant advantages is its ability to cross the blood-brain barrier. Brain metastases are a common and difficult-to-manage complication in RET-driven lung and thyroid cancers. Retevmo demonstrated meaningful intracranial response rates in patients with CNS involvement — a capability not seen with earlier RET-targeting agents. Both available strengths — Retevmo 40 mg and Retevmo 80 mg — are stocked at Elivena with full product traceability.

Taking Retevmo: Dosage Guidance and Treatment Management for RET-Positive Patients

Before starting Retevmo, confirmation of a RET gene alteration via an approved companion diagnostic test is required. Retevmo should only be prescribed to patients whose tumours harbour a RET fusion or activating RET mutation. Treatment is initiated and managed by an oncology specialist throughout the course of therapy.

Dosing is weight-based. Retevmo 80 mg is used for patients weighing 50 kg or more at a dose of 160 mg twice daily — two capsules per dose. Retevmo 40 mg is used for patients weighing less than 50 kg at a dose of 120 mg twice daily — three capsules per dose. Capsules are taken orally with or without food and must be swallowed whole. Dose modifications apply for CYP3A4 interactions, hepatic impairment, and specific adverse reactions including QTc prolongation and hypertension. Regular monitoring of liver function, ECG, and blood pressure is recommended throughout treatment.

Retevmo Supports Your Patients and Your Practice with Reliable Precision Oncology Access

By incorporating Retevmo into your oncology supply through Elivena, you are ensuring your patients receive authenticated, Canadian-sourced treatment without supply disruptions. Elivena’s oncology account team supports providers, clinics, and distributors with supply planning, formulary documentation, bulk ordering, and ongoing coordination. Order Retevmo through our secure platform and access pharmaceutical-grade, verified product with confidence.

For a complete overview of precision oncology products available through Elivena, browse the Oncology category. Our account team is available to discuss tailored supply arrangements and pricing for high-volume or ongoing orders.

How Retevmo Targets RET Kinase Activity and Delivers Antitumour Action

The active ingredient in Retevmo is selpercatinib — a small molecule, ATP-competitive kinase inhibitor built using structure-based drug design to fit precisely into the RET kinase domain. Once bound, selpercatinib prevents the oncogenic RET protein from transmitting the growth signals that cancer cells depend on. Without those signals, tumour cells stop proliferating and begin to die.

The defining design principle of selpercatinib is selectivity. Earlier multikinase inhibitors such as cabozantinib and vandetanib also inhibited RET, but their broad activity across other kinases — particularly VEGFR2 — produced significant off-target toxicities including severe hypertension, hand-foot syndrome, and gastrointestinal complications. Selpercatinib was engineered to spare those kinases, delivering superior clinical efficacy with a more manageable tolerability profile. Selpercatinib also retains activity against known acquired resistance mutations including RET G810 solvent front variants, supporting durable disease control over time.

Retevmo and Precision Medicine: The Clinical Evidence Transforming RET-Driven Cancer Treatment

The LIBRETTO-001 trial is the global, multicenter, open-label phase I/II study that established the evidence base for Retevmo across RET-altered tumour types. Enrolment included patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, RET fusion-positive thyroid cancer, and other RET-altered solid tumours across multiple international sites.

In treatment-naive RET fusion-positive NSCLC patients, the confirmed objective response rate was 84%, with a median duration of response exceeding 20 months. In previously treated patients, the ORR was 64% — confirming activity across all lines of therapy. For RET-mutant MTC, responses were consistent and durable regardless of prior treatment history. Subsequent analyses have demonstrated intracranial efficacy, activity against rare tumour histologies, and outcomes in patients with specific resistance mutations, further deepening the evidence base.

Retevmo and Targeted Therapy: Expanding Benefits Beyond the Primary Tumour Site

While Retevmo was developed for the primary treatment of RET-altered NSCLC and thyroid cancers, its clinical utility continues to expand. Ongoing studies are exploring selpercatinib’s activity in RET-altered tumour types beyond its current approved indications — including colorectal cancer, pancreatic cancer, and other rare solid tumours where RET alterations have been identified. The breadth of RET’s oncogenic role across histologies positions Retevmo as a potentially broader precision oncology tool as the evidence continues to develop.